Literature DB >> 2787356

Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo.

G Y Ishioka1, S Colon, C Miles, H M Grey, R W Chesnut.   

Abstract

The present study investigated the possibility that protein Ag fragments in the form of peptides could serve as the priming Ag in the generation of a MHC class I-restricted immune response. Trypsin-digested chicken ovalbumin (OVA-TD) fragments were used as the model Ag. The results demonstrate the peptides within OVA-TD, when injected into C57BL/6 mice, could prime T cells which lysed H-2b Ia-EL4 target cells in an OVA-TD-specific manner. In contrast to priming with OVA-TD, immunization of mice with intact OVA did not lead to generation of CTL against OVA-TD or OVA. Furthermore, target cells sensitized with intact OVA failed to be recognized by OVA-peptide-specific CTL indicating that the target cells serving as APC were unable to generate the relevant peptide determinants recognized by the T cells. These results support the idea that the processing pathway within APC for class I-restricted T cells may differ from that used for class II-restricted T cells. Using OVA-TD-specific CTL clones (phenotypically Thy 1+, CD8+, CD4-, Pgp-1+) isolated from primed animals to screen OVA-TD fractions separated by HPLC, two T cell peptide determinants were identified corresponding to OVA sequences 111-122 and 370-381. Both determinants were recognized by CTL clones in the context of the H-2Db molecule.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787356

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Specificity, restriction and effector mechanisms of immunoregulatory CD8 T cells.

Authors:  M Vukmanovic-Stejic; M J Thomas; A Noble; D M Kemeny
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

2.  Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route.

Authors:  A M Mowat; A M Donachie; G Reid; O Jarrett
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

3.  Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides.

Authors:  C D Partidos; P Vohra; M W Steward
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

4.  Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

Authors:  M K Hart; K J Weinhold; R M Scearce; E M Washburn; C A Clark; T J Palker; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

Review 5.  Peptide presentation by class-I major histocompatibility complex molecules.

Authors:  J Nikolić-Zugić; F R Carbone
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 6.  The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies.

Authors:  Denise L Faustman; Miriam Davis
Journal:  J Mol Med (Berl)       Date:  2009-08-21       Impact factor: 4.599

7.  Peptide-induced antiviral protection by cytotoxic T cells.

Authors:  M Schulz; R M Zinkernagel; H Hengartner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

8.  Mutations inside but not outside the peptide binding cleft of the H-2 Ld molecule affect CTL recognition and binding of the nucleoprotein peptide from the lymphocytic choriomeningitis virus.

Authors:  C E Hioe; D M McKinney; J A Frelinger; M McMillan
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

9.  Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein.

Authors:  A Bertoletti; F V Chisari; A Penna; S Guilhot; L Galati; G Missale; P Fowler; H J Schlicht; A Vitiello; R C Chesnut
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway.

Authors:  C Walker; M Selby; A Erickson; D Cataldo; J P Valensi; G V Van Nest
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.